Development and validation of a new HPLC analytical method for the determination of alprazolam in tablets.
A new analytical method is developed together with its latter validation study, by means of a high resolution liquid chromatography (HPLC) of reverse phase to quantify alprazolam (8-chloro-1-methyl-6-phenyl-4H-[1,2,4] triazole [4,3,-alpha]-[1,4] benzodiazepine) in tablets. Determination is carried out by means of an ODS C18 column (200 mm x 4.6 mm i.d., 5 microm particle size); the mobile phase consisted of a mixture of 0.02 M buffer solution of phosphates (pH 6.0) and acetonitrile (45:55, v/v). It is pumped through the chromatographic system at a flow rate of 0.50 ml min(-1). The UV detector is operated at 254 nm. The validation study is carried out fulfilling the ICH guidelines in order to prove that the new analytical method, meets the reliability characteristics, and these characteristics show the capacity of an analytical method to keep, throughout the time, the fundamental criteria for validation: selectivity, linearity, precision, accuracy and sensitivity. The method is applied during the working day for the quality control of commercial alprazolam tablets in order to quantify the drug and its degradation products and to check the content uniformity test.